Key facts
- SonoClear’s last known valuation is $30.6M (Jun 2025).
- It has raised $9.7M; the latest was Later Stage VC ($4.5M) in Jun 2025.
- Notable investors include CoFounder, SINTEF Venture, Sarsia Management, Sparebank 1 Smn Invest.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for SonoClear
- ·The full record, as it builds
Funding rounds
No funding rounds for SonoClear are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SonoClear
Developer of an intra-operative ultrasonography technology designed to identify tumor remnants in brain cancer. The company has developed an advanced acoustic coupling fluid (ACF) for use in ultrasound-guided brain tumor surgery, that simulates the damping of acoustic waves in normal brain tissue, enabling surgeons to identify tumors far more precisely and providing a powerful clinical tool to achieve total removal of brain tumors.
- Sector
- Healthcare
- HQ
- Oslo, Norway
- Founded
- 2016
- Employees
- 8
- Website
- sonoclear.no/
- Ownership
- Privately Held (backing)
SonoClear doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SonoClear shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SonoClear in its N-PORT filings yet. We sweep new filings monthly.